Free tool
FAERS Monitor: Cequa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210913 or its brand name (Cequa, Cyclosporine). Reports on generic versions are filed under their own applications.
Reports
60,833
Serious
52,137
86% of reports
Hospitalization
17,589
Death reported
11,014
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective8,262
- off label use7,937
- product use in unapproved indication3,648
- pyrexia2,809
- diarrhoea2,261
- condition aggravated2,214
- nausea2,087
- pneumonia2,006
- cytomegalovirus infection1,948
- eye irritation1,799
- headache1,761
- fatigue1,757
- hypertension1,733
- sepsis1,689
- rash1,667
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 881 |
| 2005 | 900 |
| 2006 | 1,029 |
| 2007 | 984 |
| 2008 | 1,675 |
| 2009 | 1,917 |
| 2010 | 1,635 |
| 2011 | 2,284 |
| 2012 | 1,609 |
| 2013 | 734 |
| 2014 | 794 |
| 2015 | 764 |
| 2016 | 955 |
| 2017 | 1,235 |
| 2018 | 1,752 |
| 2019 | 2,446 |
| 2020 | 4,018 |
| 2021 | 3,913 |
| 2022 | 5,615 |
| 2023 | 5,816 |
| 2024 | 8,274 |
| 2025 | 6,872 |
| 2026 | 4,725 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,993,326 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytomegalovirus infectionSignal | 1,948 | 45.8 | 43.7 | 75,330 |
| eye irritationSignal | 1,799 | 11.1 | 10.6 | 16,090 |
| sepsisSignal | 1,689 | 5.3 | 5.1 | 5,831 |
| product use in unapproved indicationSignal | 3,648 | 5.2 | 5.0 | 12,160 |
| off label useSignal | 7,937 | 3.2 | 3.1 | 12,066 |
| hypertensionSignal | 1,733 | 2.8 | 2.7 | 2,074 |
| pyrexiaSignal | 2,809 | 2.8 | 2.7 | 3,330 |
| condition aggravatedSignal | 2,214 | 2.5 | 2.4 | 2,060 |
| drug ineffectiveSignal | 8,262 | 2.2 | 2.1 | 5,558 |
| pneumoniaSignal | 2,006 | 2.1 | 2.1 | 1,243 |
| rash | 1,667 | 1.3 | 1.3 | 134 |
| diarrhoea | 2,261 | 1.2 | 1.2 | 86 |
| headache | 1,761 | 1.0 | 0.9 | 2 |
| nausea | 2,087 | 0.9 | 0.9 | 19 |
| fatigue | 1,757 | 0.8 | 0.7 | 113 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.